Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.40 |
| ▸ | F2R | P25116 | 10/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932935 | 0.99 | F2R (0.48) | F2RMAOBSLC22A12ALOX5PTGS1 | |
| Bromide SCHEMBL2954116 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2ABCHEACHE | |
| Bromide SCHEMBL27893556 | 0.80 | ALDH1A1 (0.48) | MEN1KMT2ABCHEACHE | |
| SCHEMBL6939772 | 0.78 | ALDH1A1 (0.46) | MEN1KMT2ABCHEACHE | |
| Bromide SCHEMBL3853603 | 0.78 | KMT2A (0.43) | F2RALOX5PTGS1PTGS2MEN1 | |
| SCHEMBL3964631 | 0.77 | KMT2A (0.44) | F2RALOX5PTGS1PTGS2MEN1 | |
| Bromide SCHEMBL3854344 | 0.75 | MAPT (0.48) | BCHE | |
| Bromide SCHEMBL3968333 | 0.74 | MAPT (0.53) | BCHEACHE | |
| SCHEMBL6939314 | 0.74 | GSK3B (0.47) | KMT2ABCHE | |
| Bromide SCHEMBL3853734 | 0.74 | CYP3A4 (0.42) | F2RALOX5PTGS1PTGS2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2009051804-A1 | THIAZOLIUM COMPOUNDS FOR TREATING OR PREVENTING DISEASES ASSOCIATED WITH INSULIN RESISTANCE | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009042213-A1 | METHODS OF TREATING OR PREVENTING CARDIAC DISEASE ASSOCIATED WITH A HIGH FAT DIET | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009023207-A1 | THIAZOLIUM COMPOUNDS FOR TREATING GASTROINTESTINAL COMPLICATIONS | SYNVISTA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | disclosed |
| EP-0808163-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON, INC. (US) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996022095-A2 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | ACHE 3514/4885F2R 1569/4885MAOB 2059/4885 |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | ACHE 909/4885F2R 2902/4885MAOB 550/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | ACHE 32/4885F2R 2584/4885MAOB 664/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | ACHE 1413/4885F2R 552/4885MAOB 790/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | ACHE 1116/4885F2R 1318/4885MAOB 563/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | ACHE 1945/4885F2R 669/4885MAOB 676/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | ACHE 657/4885F2R 2056/4885MAOB 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.